Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet

References

• Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, . Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905–14.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, . Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041–7.
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, . Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–47.
   PubMed Web of Science ®Google Scholar
• Comella P, Massidda B, Filippelli G, Palmeri S, Natale D, Farris A, . Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRI-FAFU) in patients with metastatic colorectal carcinoma: A Southern Italy Cooperative Oncology Group phase III trial. Ann Oncol 2005;16:878–86.
   PubMedGoogle Scholar
• Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, . A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23–30.
   PubMed Web of Science ®Google Scholar
• Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, . FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229–37.
   PubMed Web of Science ®Google Scholar
• Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, . Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico dell’Italia Meridionale. J Clin Oncol 2005;23:4866–75.
   PubMed Web of Science ®Google Scholar
• Conroy T, Bleiberg H, Glimelius B. Quality of life in patients with advanced colorectal cancer: What has been learnt? Eur J Cancer 2003;39:287–94.
   PubMedGoogle Scholar
• Byrne C, Griffin A, Blazeby J, Conroy T, Efficace F. Health-related quality of life as a valid outcome in the treatment of advanced colorectal cancer. Eur J Surg Oncol 2007;33 (Suppl 2):S95–S104.
   PubMedGoogle Scholar
• Seymour MT, Maughan TS, Wasan HS, Brewster AE, Shepherd SF, O’Mahoney MS, . Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with meta-static colorectal cancer: The FOCUS2 trial. J Clin Oncol 2007;25(18S):9030.
   Google Scholar
• Glimelius B, Hoffman K, Olafsdottir M, Păhlman L, Sjődén P, Wennberg A. Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: A randomized comparison of two regimens. Eur J Cancer Clin Oncol 1989;25:829–35.
   PubMedGoogle Scholar
• Maughan TS, James RD, Kerr DJ, Ledermann JA, McArdle C, Seymour MT, . Comparison of survival, palliation, and quality of life with three chemotherapy regimens in meta-static colorectal cancer: A multicentre randomised trial. Lancet 2002;359:1555–63.
   PubMed Web of Science ®Google Scholar
• Hill M, Norman A, Cunningham D, Findlay M, Watson M, Nicolson V, . Impact of protracted venous infusion fluor-ouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol 1995;13:2317–23.
   PubMed Web of Science ®Google Scholar
• Sullivan BA, McKinnis R, Laufman LR. Quality of life in patients with metastatic colorectal cancer receiving chemotherapy. A randomized, double-blinded trial comparing 5-FU versus 5-FU with leucovorin. Pharmacotherapy 1995;15:600–7.
   Google Scholar
• Köhne CH, Wils J, Lorenz M, Schöffski P, Voigtmann R, Bokemeyer C, . Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 2003;21:3721–8.
   PubMed Web of Science ®Google Scholar
• Comella P, Massidda B, Filippelli G, Farris A, Natale D, Barberis G, . Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients. Results of the Southern Italy Cooperative Oncology Group study 0401. J Cancer Res Clin Oncol 2009;135:217–26.
   PubMedGoogle Scholar
• Efficace F, Bottomley A, Vanvoorden V, Blazeby JM. Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials. Eur J Cancer 2004;40:187–97.
   PubMed Web of Science ®Google Scholar
• Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J. Analysis and interpretation of health-related quality of life data from clinical trials: Basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005;41:280–7.
   PubMed Web of Science ®Google Scholar
• Petersen MA, Larsen H, Pedersen L, Sonne N, Groenvold M. Assessing health-related quality of life in palliative care: Comparing patient and physician assessments. Eur J Cancer 2006;42:1159–66.
   PubMed Web of Science ®Google Scholar
• Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer 2002;38:1351–7.
   PubMed Web of Science ®Google Scholar
• Grothey A, Sargent D, Goldberg RM, Schmoll H-J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxalipla-tin in the course of treatment. J Clin Oncol 2004;22:1209–14.
   PubMed Web of Science ®Google Scholar
• Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, iri-notecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005;23:9441–2.
   PubMed Web of Science ®Google Scholar
• Earlam S, Glower C, Fordy C, Burke D, Allen-Mersh TG. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol 1966;14:171–5.
   Google Scholar
• Lis CG, Gupta D, Granick J, Grutsch JF. Can patient satisfaction with quality of life predict survival in advanced color-ectal cancer? Support Care Cancer 2006;14:1104–10.
   PubMedGoogle Scholar
• Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schöffski P, . Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? Eur J Cancer 2006;42:42–9.
   PubMed Web of Science ®Google Scholar
• Efficace F, Innominato PF, Bjarnason G, Coens C, Humblet Y, Tumolo S, . Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: Results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2008;26:2020–6.
   PubMed Web of Science ®Google Scholar
• Turja JH, Grothey A, Sargent DJ, Szydlo DW, Zhao X, Campbell ME, . Use of baseline quality of life (QOL) as compared with performance status (PS) as prognostic factors for overall survival (OS) in patients with metastatic colorec-tal cancer (mCRC). J Clin Oncol 2008;26(20S):4016.
   Google Scholar
• Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008;26:1355–63.
   PubMed Web of Science ®Google Scholar